SUMMARY We studied retrospectively levels of antimyelin antibody in a group of 13 multiple sclerosis patients who underwent a clinical trial of long-term, high dose (2.0-4.5 mg/kg/day) azathiaprine therapy. In apparent contrast with collagen vascular disease associated with antitissue antibody, azathiaprine therapy was not associated with significant change in titres of antimyelin antibody. Variation of titre of antimyelin antibody in apparent association with disease activity continued during therapy. No significant changes occurred in levels of serum immunoglobulins.
Humoral immune responses to nervous system constituents such as myelin have been demonstrated in several nervous system diseases, especially multiple sclerosis. An indirect immunofluorescent technique for demonstrating serum immunoglobulin binding to myelin and glial cells was first reported by Allerand and Yahr (1964) . Subsequently Edgington and D'Alessio (1970) used a similar technique to show significantly higher titres of myelin binding activity in sera of multiple sclerosis patients than in sera of normal subjects. Work here Swanson and Schwartz, 1967) , we studied retrospectively the pattern of antimyelin antibody during the course of treatment in the group of multiple sclerosis patients reported . We report these results as further evidence of the failure of induced immunosuppression to influence the course of multiple sclerosis.
Patients and methods
Sera obtained from a group of multiple sclerosis patients before, during, and after a clinical trial of azathiaprine, 2.0-4.5 mg/kg/day, were coded and stored at -70°C until used in blind analysis. Samples were obtained at predetermined intervals independent of clinical status. The clinical characteristics and outcome of the group were reported earlier .
Serum immunoglobulin G (IgG) was assayed by radial immunodiffusion (Mancini et al., 1965) Comparison of 'the clinical courses and sequential antimyelin antibody titres in individual patients during azathiaprine therapy showed a pattern in all but two patients similar to that reported previously in a small group of untreated patients with multiple sclerosis , titres tending to be raised during times of apparent increased activity of the disease.
The mean serum IgG before azathiaprine was 14.69 g/l which is slightly, but not significantly higher than the established mean for normals (10.55 g/l) in our laboratory . Sequential values for group mean serum IgG levels ( (Edgington and D'Alessio, 1970; have shown characteristics of this reaction that are similar to those of antibodies. For example, the reaction is blocked by previous exposure of the tissue substrate to experimentally induced rabbi't antimyelin antiserum but not by normal rabbit serum . This would suggest specific binding by the Fab portion of the immunoglobulin molecule in the multiple sclerosis sera studied. On the other hand, there is evidence for some non-specific binding by the Fc portion (Aarli et al., 1975) . These sets of observations do not imply mutually exclusive propositions. Regardless, independent studies (Edgington and D'Alessio, 1970; show increase in activity of this tentative antibody in patients with demyelinative disease and, possibly, a direct association of active disease phases with higher titres. Data presented here show that continued fluctuations of levels of antimyelin antibody occur despite azathiaprine treatment, and that these fluctuations tend to correlate with periods of disease quiescence and activity. This observation appears in striking contrast to the situation of anti-tissue antibodies in collagen vascular diseases in which azathiaprine induced immunosuppression typically is associated with a diminution of antitissue antibody levels before or even without clinical improvement (Swanson and Schwartz, 1967; Levin et al., 1964) . Therefore, it appears that azathiaprine treatment not only failed to alter the clinical course but also failed to alter what tentatively appears to be an immunological parameter. Relegation of this observation to a difference in the nature or quality of immunosuppression induced in the group is not likely although the present group is unique for the long-term use of a single agent in non-debilitated patients.
Explanation of the apparent resistance of antimyelin antibody to azathiaprine induced immunosuppression may lie with a difference between primary and secondary responses in sensitivity to immunosuppression. In several studies (Swanson and Schwartz, 1967; Levin et al., 1964; Davis et al., 1972) azathiaprine and related agents have suppressed responses to newly met antigens, primary responses, more than levels of previously existing antibody. As reported by Zweiman et al. (1973) , similar effects of azathiaprine treatment were seen in this group with marked reduction in delayed hypersensitivity responses to newly met antigens and occasional, milder reductions of delayed hypersensitivity responses to previously acquired antigens. There was no reduction in humoral responses to previously met antigens. Finding of low levels of antimyelin antibody in many normal sera (Edgington and D'Alessio, 1970; suggest that immune reactivity against myelin has commonly occurred early in postnatal life and its fluctuations might be similar to secondary responses.
A small number of patients with multiple sclerosis have mildly raised serum immunoglobulin levels (Link and Muller, 1971; Kabat et al., 1950) so that finding of slight elevation of the group mean IgG is not surprising in a small group. This level remained unchanged during immunosuppression as previously reported (Davis et al., 1972; Jones et al., 1975) .
